Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tacrolimus
Drug ID BADD_D02105
Description Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex inhibits calcineurin which inhibits T-lymphocyte signal transduction and IL-2 transcription.
Indications and Usage For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was given FDA approval in 1994 for use in liver transplantation. Since then, this indication has expanded to kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
Marketing Status approved; investigational
ATC Code D11AH01; L04AD02
DrugBank ID DB00864
KEGG ID D00107; D08556
MeSH ID D016559
PubChem ID 445643
TTD Drug ID D06OMK
NDC Product Code 0904-6623; 51927-0092; 65897-3010; 68254-0020; 73377-010; 16729-041; 16729-421; 0093-3428; 63629-8726; 0378-2045; 67877-279; 67877-280; 68254-5006; 68992-3010; 68992-3075; 0469-1230; 70518-3216; 38779-2698; 47848-018; 49629-020; 51187-0006; 65050-0321; 68254-2502; 0093-3429; 43817-421; 50222-211; 55111-527; 63629-9325; 64380-721; 0378-2047; 68084-450; 68308-703; 70518-2996; 0904-6624; 0168-0416; 45802-390; 45802-700; 51079-028; 51079-818; 55111-526; 68462-686; 0469-0607; 70748-221; 60429-378; 68254-5005; 68462-534; 70377-014; 70748-220; 65897-1010; 16714-100; 0378-2046; 67877-278; 68462-687; 70377-015; 70518-3388; 49629-022; 52076-6222; 16729-042; 16729-422; 51079-817; 68084-449; 0469-1330; 69452-154; 69452-155; 72572-761; 82983-401; 82983-402; 16714-098; 55111-525; 60429-379; 63629-8725; 68084-451; 0469-0657; 71335-2189; 72572-760; 49629-021; 52928-006; 62991-3072; 50090-5596; 50222-203; 54288-135; 55154-4168; 68254-5004; 0469-0617; 0469-3016; 0781-2102; 0781-2103; 82983-400; 0168-0417; 43817-423; 55154-4080; 60429-377; 68992-3040; 70377-016; 82160-124; 55500-0010; 65727-009; 68254-0002; 43353-317; 43817-422; 62250-665; 63629-8723; 64380-720; 64380-722; 68462-685; 69452-153; 70748-219; 0781-2104; 0904-7097; 51552-1403; 52972-0040; 55486-1576; 16714-099; 16729-043
UNII WM0HAQ4WNM
Synonyms Tacrolimus | Prograf | Prograft | FR-900506 | FR 900506 | FR900506 | Anhydrous Tacrolimus | Tacrolimus, Anhydrous | Tacrolimus Anhydrous | Anhydrous, Tacrolimus | FK-506 | FK 506 | FK506
Chemical Information
Molecular Formula C44H69NO12
CAS Registry Number 104987-11-3
SMILES CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC 4CCC(C(C4)OC)O)C)O)C)OC)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysgraphia17.02.03.006--Not Available
Biopsy bile duct abnormal13.03.02.001--Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Hypoperfusion24.06.02.0190.000446%Not Available
Hepatic vein occlusion24.04.07.005; 09.01.06.0110.000297%Not Available
Application site discolouration12.07.01.030; 08.02.01.030; 23.03.03.0230.000297%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000653%Not Available
Incision site complication12.02.05.012--Not Available
Ventricular dysfunction02.04.02.005--Not Available
Cerebral vasoconstriction24.04.06.025; 17.08.02.0120.000743%Not Available
Intestinal haemorrhage24.07.02.031; 07.12.03.0050.001337%Not Available
Juvenile idiopathic arthritis15.01.03.004; 10.04.06.0040.000297%Not Available
Perinephric collection20.02.03.014; 12.01.05.0030.000297%Not Available
Angiopathy24.03.02.0070.000446%Not Available
Anogenital warts23.10.01.003; 21.10.03.004; 16.26.01.003; 11.05.07.002; 07.19.04.0020.001188%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Adhesion08.01.03.0480.000297%Not Available
Drug resistance08.06.01.005--Not Available
Haemorrhagic ovarian cyst16.04.03.003; 24.07.03.014; 21.11.01.0070.000743%Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Neurological symptom17.02.05.0100.001634%Not Available
Prostate cancer21.04.02.002; 16.25.01.001--Not Available
Aortic rupture24.03.04.009; 12.01.11.0070.000594%Not Available
Monoclonal gammopathy16.23.01.003; 01.14.01.0030.000446%Not Available
Freezing phenomenon17.01.05.0060.000297%Not Available
Bacterial infection11.02.01.005--Not Available
Benign neoplasm16.02.02.007--Not Available
Biliary tract disorder09.02.03.0010.000594%Not Available
Bladder disorder20.03.01.002--Not Available
The 30th Page    First    Pre   30 31 32 33 34    Next   Last    Total 41 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene